NCT05521035

Brief Summary

What is the risk of aortic vascular graft and endograft infection in patients with aortic vascular graft/endograft and bloodstream infection?

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 26, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 30, 2022

Completed
2 days until next milestone

Study Start

First participant enrolled

September 1, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

December 14, 2023

Status Verified

December 1, 2023

Enrollment Period

2 years

First QC Date

August 26, 2022

Last Update Submit

December 11, 2023

Conditions

Aortic Infections and Inflammations

Outcome Measures

Primary Outcomes (1)

  • Aortic vascular graft or endograft infection

    Determined by the MAGIC-criteria

    At least 1 year follow-up

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients with previous aortic vascular graft or endograft surgery in Skåne, Halland, Kronoberg and Blekinge between the years 2010-2021.

You may qualify if:

  • Previous aortic vascular graft or endograft infection with bloodstream infection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Helsingborgs lasarett

Helsingborg, Sweden

RECRUITING

Related Links

MeSH Terms

Conditions

Inflammation

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Oskar Ljungquist

    Lund University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Oskar Ljungquist, M.D, PhD

CONTACT

+46424061000oskar.ljungquist@med.lu.se

Torgny Sunnerhagen, M.D, PhD

CONTACT

torgny.sunnerhagen@med.lu.se

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 26, 2022

First Posted

August 30, 2022

Study Start

September 1, 2022

Primary Completion

September 1, 2024

Study Completion

September 1, 2024

Last Updated

December 14, 2023

Record last verified: 2023-12

Locations

SE(1)